drugset / Trial / NCT02998931

Trial of Enteral Glutamine on Clinical Outcomes in Critically Ill Patients

NCT02998931

Phase 3 Completed 200 enrolled Shahid Beheshti University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Glutamine supplementation has beneficial effects on morbidity and mortality in critically ill patients, possibly in part through an attenuation of the proinflammatory cytokine response and a Immune function. In this trial intensive care unit patients with enteral feeding will receive either enteral glutamine or maltodextrin as placebo for 28 days.

Timeline

Start
2016-11-10
Primary completion
2018-08-25
Completion
2018-09-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Glutamine Other / unclassified 0.3 g/kg Other